Biomarkers, Cancer Therapy & Clinical Research

Epigenetic Biomarkers

Epigenetic biomarkers play a crucial role in elucidating how environmental exposures, lifestyle factors, and aging influence gene regulation without altering the underlying DNA sequence. These biomarkers—including DNA methylation patterns, histone modifications, and regulatory non-coding RNAs—provide valuable insights into disease risk, progression, and therapeutic response. In cancer research, epigenetic alterations such as aberrant DNA methylation of tumor suppressor genes and deregulated microRNA expression are closely linked to tumor initiation, progression, and treatment resistance. These biomarkers serve not only as prognostic and predictive indicators but also as promising targets for epigenetic therapies. Beyond oncology, epigenetic biomarkers are increasingly investigated in cardiovascular, neurodegenerative, metabolic, and autoimmune disorders. They support personalized medicine approaches by enabling prediction of treatment response and guiding individualized therapeutic strategies based on patient-specific epigenetic profiles. The ongoing discovery and clinical validation of epigenetic biomarkers are advancing precision medicine, enhancing early disease detection, and improving patient outcomes through targeted, mechanism-based interventions.